| Stage | LBRDK | % of rev | CMCSA | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $246M | 100.00% | $29.3B | 100.00% | CMCSA ×119.10 |
| Gross profit | $246M | 100.00% | $21.8B | 74.35% | LBRDK +25.7pp |
| Operating income | $21M | 8.54% | $5.3B | 18.16% | CMCSA +9.6pp |
| Pre-tax income | $253M | 102.85% | $4.4B | 15.18% | LBRDK +87.7pp |
| Net income | $195M | 79.27% | $3.4B | 11.48% | LBRDK +67.8pp |
| Stage | LBRDK | CMCSA | Gap · A − B |
|---|---|---|---|
| Revenue | $246M100.00% | $29.3B100.00% | CMCSA ×119.10 |
| Gross profit | 100.00%$246M | 74.35%$21.8B | LBRDK +25.7pp |
| Operating income | 8.54%$21M | 18.16%$5.3B | CMCSA +9.6pp |
| Pre-tax income | 102.85%$253M | 15.18%$4.4B | LBRDK +87.7pp |
| Net income |
| 79.27%$195M |
| 11.48%$3.4B |
| LBRDK +67.8pp |
None
No disclosed counterparties: LBRDK.